What’s in a name? When it comes to PCOS, a lot

The long-standing name 'polycystic ovary syndrome' (PCOS) is being officially replaced with 'Polyendocrine Metabolic Ovarian Syndrome' (PMOS) after a 14-year international effort to correct a decades-old misnomer. The change, led by Dr. Anuja Dokras and a coalition of clinicians, patients, and researchers, addresses the fact that PCOS has no actual cysts—only tiny follicles—and that the condition is far more than a reproductive issue. It encompasses metabolic, psychological, and cardiometabolic risks, yet the old name perpetuated stigma and delayed diagnosis. The new name reflects the syndrome’s systemic nature, aiming to improve early detection, reduce patient confusion, and unlock broader research funding across specialties like endocrinology and cardiology. Despite some pushback over branding and implementation, the response has been overwhelmingly positive, with patients and advocates calling the change long overdue and refreshingly subtle—just one letter shifted in the acronym. The rebranding process was unprecedented in scale and inclusivity, involving over 22,000 surveys, 50+ medical societies, and 90 global stakeholders, including patients and clinicians from diverse fields. Using a rigorous Delphi method, the group iteratively refined the name based on scientific accuracy, cultural sensitivity, and ease of adoption.